Clinical trials: Coats Retinopathy
Retinopathy of Prematurity Both Eyes, Retinal Disease
Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries
This study aims to study the safety and efficacy of using an 18 mm short vitrectomy probe for pediatric vitreoretinal surgeries and to investigate the surgeon's comfort and reliability of using the shorter probe.
- Conditions
- Retinopathy of Prematurity Both Eyes, Retinal Disease, Persistent Fetal Vasculature, Coats Disease
- Trial name
- NCT06520410
- Testing
- Pars plana vitrectomy with a 18 mm short vitrector
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Vitreoretinopathy, Coats' Disease
DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia
The Tender Study is a prospective, open-label, single-center, randomized, investigator-initiated clinical study seeks to investigate the safety and efficacy of the DEXTENZA insert in pediatric patients following retinal surgery…
- Conditions
- Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration
- Trial name
- NCT05620901
- Testing
- Dextenza 0.4Mg Ophthalmic Insert, Pred Forte
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Lejla Vajzovic, MD, FASRS
Coats Disease
Coats Plus Syndrome and LCC Syndrome: Series of 10 Pediatric Cases. Review of Literature and Natural History
Coats plus syndrome is a very rare and serious disease, caused by premature telomere shortening. It is a pediatric, multi-systemic disease, the main features of which are retinal vasculopathy and neurological disorders…
- Trial name
- COATS+ (NCT04089995)
- Testing
- data collection
- Where
- 6 sites in France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Limoges
Retinal Telangiectasis, Coats Disease
Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
Coats disease is a predominantly unilateral progressive retinal vascular disease, characterized by retinal telangiectasias with intra- or subretinal exudate deposits, which can lead to retinal detachment and one-sided blindness.
- Trial name
- COATS-VEGF (NCT03940690)
- Testing
- Anti-VEGF injections of bevacizumab, Laser
- Where
- 6 sites in France
- Volunteers
- 18 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild